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1ABSTRACT
The effect of metformin on recurrence of colorectal adenoma in diabetic 
patients with previous colorectal adenoma
Min Seok Han
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Tae Il Kim)
Existing studies suggest that metformin lowers the risk and mortality 
of colorectal cancer. However, the effect of metformin on the suppression and 
prevention of colorectal adenomas is not clear. The aim of this study was to 
evaluate the effect of metformin on the recurrence of colorectal adenoma in 
diabetic patients with previous colorectal adenoma. Among 423 diabetic 
patients who underwent surveillance colonoscopy after resection of colorectal 
adenoma between 2005 and 2011, 257 patients were retrospectively reviewed. 
The patients were divided into two groups: one group comprising 106 patients 
who took metformin and another group comprising 151 patients who did not 
take metformin. The clinical characteristics, colorectal adenoma recurrence, and 
valuable factors for adenoma recurrence were analyzed. At surveillance 
colonoscopy after colonoscopic polypectomy for adenoma, 38 patients (35.8%) 
exhibited colorectal adenoma among 106 patients who took metformin, 
compared with 85 patients (56.3%) with colorectal adenoma among 151 
patients who did not take metformin (odds ratio 0.434, 95% confidence interval 
20.260-0.723, P = 0.001). Multivariate Cox analysis showed that metformin was 
associated with decreased recurrence of colorectal adenoma (hazard ratio 0.572, 
95% confidence interval 0.385-0.852, P = 0.006) in diabetic patients with 
previous colorectal adenoma. The cumulative probability of colorectal adenoma 
recurrence was significantly lower in the metformin group than in the 
non-metformin group (P = 0.001). Metformin use in diabetic patients with 
previous colorectal adenoma is associated with a lower risk of colorectal 
adenoma recurrence.
-----------------------------------------------------------------------------------------------
Key words: Metformin, Colorectal adenoma, Recurrence, Diabetes mellitus
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Min Seok Han
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Tae Il Kim)
I. INTRODUCTION
Colorectal cancer (CRC) is a common neoplasm worldwide and the third 
main cause of cancer related death.1 Colorectal adenoma is a precursor of 
colorectal cancer according to the adenoma-carcinoma sequence.2,3 Suppression 
and removal of colorectal adenoma is very important for preventing colorectal 
cancer.4 Recent studies proved that non steroidal anti-inflammatory drugs and
cyclooxygenase-2 inhibitors have chemopreventive effects against colorectal 
adenoma and cancer.5-7 However, they have increased risks of gastrointestinal 
bleeding and cardiovascular accidents.8 Thus, they are not usually used for 
chemoprevention, except for limited use in patients with very high CRC risk. 
Therefore, new drugs that are safe and effective for the prevention of colorectal 
adenoma are needed.
Epidemiological studies have shown that the risk of several types of 
4cancer, including cancer of the pancreas, liver, breast, colorectum, urinary tract, 
and female reproductive organs, is increased in patients with diabetes.9 The 
mortality of these cancers is also moderately increased in patients with diabetes. In 
addition, diabetes mellitus is an independent risk factor for colorectal cancer, and
diabetic patients with colorectal cancer have worse outcomes than non-diabetic 
patients.10 Moreover, hyperinsulinemia most likely increases the risk of cancer in 
patients with diabetes, as insulin is a growth factor with preeminent metabolic and 
mitogenic effects.
Recently, metformin, a biguanide derivative oral diabetic agent, was 
reported to have a tumor-suppressive effect. Concerning its use as an anti-diabetic 
medication, metformin suppresses gluconeogenesis in the liver and reduces insulin 
resistance in peripheral organs, and shows no glucose lowering effect in 
non-diabetic patients. Moreover, metformin has been widely used for a long time 
in the treatment of type 2 diabetes mellitus and is generally considered to be a safe 
and economic drug, which means optimal candidate for a chemopreventive drug. 
The main action mechanism of metformin is related to liver kinase B1-dependent 
activation of AMP-activated protein kinase (AMPK).11 In addition, activated 
AMPK inhibits the mammalian target of the rapamycin pathway (mTOR), which 
plays a key role in cell growth and proliferation. Therefore, AMPK activation by 
metformin may have a suppressive effect on tumorigenesis and cancer cell 
growth.12 Furthermore, preclinical studies identified the anti tumor effect of 
metformin, the inhibition of tumor growth and induction of apoptosis in animals, 
and cell line models of various cancers.13
There have been some reports about the effect of metformin on decreased 
5risk and mortality of colorectal cancer. In a meta-analysis of 14 cohort studies 
revealed that the risk of colorectal cancer was significantly lower among 
metformin users than among non-metformin users (pooled risk ratio [95% 
confidence interval] 0.79 [0.69-0.91], test for overall effect Z=-3.34, P < 0.001).14
As for the mortality of colorectal cancer, a meta-analysis of 6 cohort studies, 
including our previous study, metformin users had a better overall survival (hazard 
ratio 0.56, 95% confidence interval 0.41-0.77) and a better CRC-specific survival 
(hazard ratio 0.66, 95% confidence interval 0.50-0.87) than non-metformin 
users.15
However, there have been few reports about the effect of metformin on 
the suppression and prevention of colorectal adenoma, which is the precancerous 
lesion of CRC.16,17 In our previous study, we reported the effect of metformin on 
colorectal adenomas, showing that metformin was associated with a decreased 
incidence of colorectal adenomas (odds ratio 0.27, 95% confidence interval
0.100–0.758, P = 0.012) in diabetic patients with previous CRC.18 However, 
because the patients in our previous study had colorectal cancer, the colon area of 
surveillance colonoscopy was limited owing to previous surgery, and we needed to 
prove the effect of metformin in the extended general population. Thus, we 
decided to evaluate the effect of metformin on the recurrence of colorectal 
adenoma in diabetic patients with previous colorectal adenoma.
6II. MATERIALS AND METHODS
1. Study design
A total of 423 patients with diabetes who underwent surveillance 
colonoscopy after resection of colorectal adenoma between January 2005 and 
December 2011 at Severance Hospital, Yonsei University College of Medicine in 
Seoul, Korea, were enrolled initially. Among them, 166 patients were excluded
because of the the following reasons: previous bowel resection (153 patients), poor 
bowel preparation (8 patients), familial polyposis (3 patients), and short follow-up 
duration(2 patients). Finally, 257 patients were retrospectively reviewed and 
divided into two groups: 106 patients who took metformin and 151 patients who 
did not take metformin (Fig. 1). We defined metformin takers as patients who took 
metformin ≥6 months during the follow-up duration between screening 
colonoscopy and surveillance colonoscopy.
We reviewed the medical records on age; sex; body mass index; family 
history of colorectal cancer; smoking history; diabetes mellitus duration;
medication history; laboratory findings including hemoglobin A1c(HbA1c), 
glucose, and cholesterol levels; characteristics of adenoma; and colonoscopic 
follow-up duration.
The end point of our study was the difference in the recurrence rate of 
colorectal adenoma after polypectomy between the metformin and non-metformin 
groups.
We obtained approval from the institutional review board of Severance 
Hospital, Yonsei University, Seoul, Korea.
7Figure 1. Overview of the patient selection process 
82. Colonoscopic surveillance
The patients underwent screening colonoscopy and received 
polypectomy at the same time when a polyp was detected. Then, the patients
underwent surveillance colonoscopy according to existing guidelines.19
Hyperplastic polyps and other benign mucosal lesions were not considered as 
adenomas. We reviewed recurred adenoma at surveillance colonoscopy, including
adenoma location, shape, size, and pathology. Advanced adenoma was defined as 
an adenoma that was ≥10mm in diameter and/or with high-grade pathology, 
including villous or tubulovillous component, high-grade dysplasia, and 
carcinoma.
3. Statistical analysis
We performed statistical analyses by using SPSS version 18.0 (SPSS Inc., 
Chicago, IL, USA). Grouped values were reported as mean ± standard deviation of 
mean. To examine the differences between the metformin group and the 
non-metformin group, Student’s t-test was used for continuous variables and the 
chi-square test was used for categorical variables.
We used both logistic regression and Cox regression models to evaluate 
the rate of colorectal adenoma recurrence and the valuable factors for adenoma 
recurrence. A multivariate analysis was performed for evaluation after adjusting 
for various confounders.
Kaplan–Meier and Cox proportional hazard models were used to 
evaluate the cumulative probability of colorectal adenoma development. In the 
9Kaplan–Meier model, the polyp recurrence curves of the two groups were 
compared by using a log-rank test. The Cox proportional hazard model was also 
used to evaluate the cumulative probability of colorectal adenoma development 
after adjusting for confounding factors. In each instance, 95% confidence intervals 
were also reported when available and P < 0.05 was required for statistical 
significance.
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III. RESULTS
1. Patients demographics and clinical characteristics
The median follow-up duration was 27 months (range 10-65). The 
clinical characteristics are shown in Table 1. There was no significant difference 
between the metformin and non-metformin groups in clinicopathophysiologic 
characteristics including age, sex, family history of colorectal cancer, smoking
history, diabetes mellitus duration, aspirin use, glucose level, cholesterol level, 
number of baseline adenomas, and colonoscopic follow-up duration. However, the 
metformin group showed higher body mass index and HbA1c level (P = 0.004 and 
P = 0.032, respectively), and less use of insulin (P = 0.015).
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Table 1. Clinical characteristics of the metformin and non-metformin groups
Metformin 
(n=106)
Non-Metformin 
(n=151)
P-value
Age (years) 66.5±7.0 65.5±8.1 0.327
Sex
Male
Female
76 (71.7%)
30 (28.3%)
115 (76.2%)
36 (23.8%)
0.420
Body mass index (Kg/m2) 25.4±3.5 24.2±3.0 0.004
Family History of CRC 6 (5.7%) 5 (3.3%) 0.369
Current smoker 28 (26.4%) 41 (27.2%) 0.439
DM duration (years) 8.2±4.4 9.3±4.2 0.290
Aspirin use 45 (42.5%) 67 (44.4%) 0.799
Insulin use 4 (3.8%) 19 (12.6%) 0.015
Thiazolidinedione use 11 (10.4%) 8 (5.3%) 0.149
Hba1c (%) 7.0±0.7 6.8±0.7 0.032
Glucose, AC (mg/dL) 110.3±18.3 114.0±20.7 0.388
Glucose, PC (mg/dL) 178.9±33.8 170.3±31.6 0.280
Total cholesterol (mg/dL) 179.4±23.9 176.8±27.9 0.440
Number of baseline
adenomas
2.5±2.5 2.7±2.5 0.496
Time to first follow-up
colonoscopy (days)
859±414 762±421 0.066
Values are presented as mean±standard deviation or n(%)
CRC, colorectal cancer; DM, diabetes mellitus, Hba1c, glycated hemoglobin; AC, ante 
cibum; PC, post cibos
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2. Characteristics of adenomas found in surveillance colonoscopy 
There was no significant difference in the characteristics of adenomas 
found in surveillance colonoscopy between the metformin and non-metformin 
groups except in the number of patients with recurrence of conventional adenoma 
(Table 2).
Table 2. Characteristics of adenomas found in surveillance colonoscopy in the 
metformin and non-metformin groups
Metformin
(n=106)
Non-metformin 
(n=151)
P-value
Number of polyps 0.80±1.4 0.83±1.1 0.836
Size of largest polyp, mm 2.1±4.0 2.8±3.4 0.136
Location of adenomas
Right side of colon 56 (63.6%) 63 (52.5%) 0.310
Left side of colon 23 (26.1%) 52 (43.3%) 0.076
Rectum 9 (10.2%) 5 (4.2%) 0.115
Dysplasia
Non high-grade 83 (97.6%) 115 (97.5%) 0.984
High-grade 2 (2.4%) 3 (2.5%) 0.955
Type of adenomas
Tubular adenoma 80 (94.1%) 116(98.3%) 0.929
Tubulovillous adenoma 2 (2.4%) 1 (0.8%) 0.370
Villous adenoma 3 (3.5%) 1 (0.8%) 0.386
Conventional adenoma, 
yes/no
37/69 (34.9%/65.1%) 85/66 (56.3%/43.7%) <0.001
Serrated adenoma, yes/no 3/103 (2.8%/97.2%) 2/149 (1.3%/98.7%) 0.381
Number of conventional 
adenomas
85 118 0.897
Number of serrated 
adenomas
3 2 0.392
Values are presented as mean±standard deviation or n(%)
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3. Comparison of the recurrence rate of colorectal adenoma between the 
metformin and non-metformin groups
Among a total of 257 patients, 123 (47.9%) exhibited recurrence of 
colorectal adenoma, and 2 (0.01%) exhibited colorectal cancer (Table 3). Among 
106 patients who took metformin, 38 (35.8%) exhibited colorectal adenoma, 
whereas among 151 patients who did not take metformin, 85 (56.3%) exhibited 
colorectal adenoma (odds ratio 0.434, 95% confidence interval 0.260-0.723, P = 
0.001). However, there was no significant difference in the recurrence of advanced 
adenoma and colorectal cancer.
In the subgroup analysis, the male patient group showed similar results 
(Table 4). Among 76 male patients who took metformin, 28(36.8%) exhibited 
colorectal adenoma, whereas among 115 male patients who did not take 
metformin, 70(60.9%) exhibited colorectal adenoma (odds ratio 0.375, 95% 
confidence interval 0.206-0.682, P = 0.001). However, in the female patient group, 
there was no significant difference in the recurrence of total adenoma (Table 5).
Table 3. Recurrence rate of colorectal adenoma and incidence of CRC in the 
metformin and non-metformin groups
Metformin
(n=106)
Non-metformin 
(n=151)
OR 95% CI P-value
Total adenoma 38 (35.8%) 85 (56.3%) 0.434 0.260-0.723 0.001
Advanced 
adenoma
20 (18.9%) 21 (13.9%) 1.440 0.737-2.814 0.287
CRC 1 1 1.000
CRC, colorectal cancer; OR, odds ratio; CI, confidence interval
14
Table 4. Recurrence rate of colorectal adenoma and incidence of CRC in the 
metformin and non-metformin groups (Male)
Metformin
(n=76)
Non-metformin 
(n=115)
OR 95% CI P-value
Total adenoma 28 (36.8%) 70 (60.9%) 0.375 0.206-0.682 0.001
Advanced 
adenoma
13 (17.1%) 15 (13.0%) 1.376 0.614-3.083 0.438
CRC 0 1
CRC, colorectal cancer; OR, odds ratio; CI, confidence interval
Table 5. Recurrence rate of colorectal adenoma and incidence of CRC in the 
metformin and non-metformin groups (Female)
Metformin
(n=30)
Non-metformin 
(n=36)
OR 95% CI P-value
Total adenoma 10 (33.3%) 15 (41.7%) 0.700 0.256-1.917 0.488
Advanced 
adenoma
7 (23.3%) 6 (16.7%) 1.522 0.450-5.145 0.499
CRC 1 0
CRC, colorectal cancer; OR, odds ratio; CI, confidence interval
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4. Factors affecting the recurrence rate of colorectal adenoma
After adjustment for age, sex, body mass index, diabetes mellitus 
duration, aspirin use, insulin use, thiazolidinedione use, HbA1c, number of 
baseline adenomas, and time to first follow-up colonoscopy, multivariate logistic 
regression analysis showed that metformin use was associated with decreased 
recurrence of colorectal adenomas (odds ratio 0.433, 95% confidence interval
0.256-0.732, P = 0.002) in diabetic patients with previous colorectal adenoma. 
Furthermore, the number of baseline adenomas was also related to the recurrence 
of adenoma (odds ratio 1.218, 95% confidence interval 1.085-1.368, P = 0.001). 
However, other factors including age, sex, body mass index, aspirin use, 
thiazolidinedione use, and follow-up duration did not affect the recurrence of 
adenoma (Table 6). Multivariate Cox regression analysis showed the same result:
that metformin use and the number of baseline adenomas were related to the 
recurrence of adenoma (Table 7).
The cumulative probability of colorectal adenoma recurrence was 
significantly lower in the metformin group than in the non-metformin group (log 
rank test, P = 0.001; Fig. 2). After adjusting for confounding factors, the 
cumulative recurrence rate of colorectal adenoma in the metformin group was also 
significantly lower than that in the non-metformin group (Cox proportional hazard 
model, P = 0.006; Fig. 3).
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Table 6. Logistic regression analysis of valuable factors for colorectal adenoma 
recurrence
Univariate analysis Multivariate analysis
HR 95% CI P-
value
HR 95% CI P-
value
Use of metformin 0.469 0.269-0.816 0.007 0.433 0.256-0.732 0.002
Age 0.983 0.949-1.019 0.349 0.983 0.949-1.019 0.349
Sex 0.692 0.374-1.281 0.242 0.692 0.376-1.271 0.235
Body mass index 0.953 0.873-1.041 0.286 0.959 0.879-1.046 0.344
DM duration 1.178 0.916-1.321 0.277 1.180 0.883-1.299 0.282
Aspirin use 1.597 0.916-2.786 0.099 1.518 0.899-2.563 0.118
Insulin use 1.697 0.654-4.404 0.277 1.793 0.714-4.502 0.214
Thiazolidinedione 
use
1.961 0.746-5.155 1.172 1.972 0.713-5.180 1.181
Hba1c 1.212 0.842-1.517 0.276 1.292 0.813-1.603 0.281
Number of baseline
adenomas
1.211 1.071-1.371 0.002 1.218 1.085-1.368 0.001
Time to first 
follow- up 
colonoscopy
1.000 0.999-1.000 0.216 1.000 0.999-1.000 0.212
DM, diabetes mellitus, Hba1c, glycated hemoglobin; HR, hazard ratio; CI, confidence 
interval
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Table 7. Cox regression analysis of valuable factors for colorectal adenoma 
recurrence
Univariate analysis Multivariate analysis
HR 95% CI P-
value
HR 95% CI P-
value
Use of metformin 0.541 0.369-0.795 0.002 0.572 0.385-0.852 0.006
Age 1.002 0.978-1.027 0.855 0.999 0.974-1.026 0.957
Sex 0.661 0.426-1.028 0.066 0.690 0.442-1.076 0.101
Body mass index 0.972 0.917-1.030 0.339 0.982 0.923-1.045 0.576
DM duration 1.201 0.921-1.302 0.281 1.312 0.902-1.311 0.302
Aspirin use 1.146 0.803-1.636 0.452 1.036 0.714-1.503 0.852
Insulin use 1.256 0.719-2.194 0.437 1.390 0.781-2.475 0.263
Thiazolidinedione 
use
1.394 0.767-2.536 0.276 1.837 0.991-3.405 0.093
Hba1c 1.153 0.891-1.493 0.280 1.161 0.893-1.508 0.264
Number of baseline
adenomas
1.224 1.149-1.313 0.002 1.223 1.147-1.316 0.004
DM, diabetes mellitus, Hba1c, glycated hemoglobin; HR, hazard ratio; CI, confidence 
interval
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Figure 2. Cumulative recurrence rate of colorectal adenoma
P = 0.001
19
Figure 3. Cumulative recurrence rate of colorectal adenoma after adjusting 
related factors 
P = 0.006
20
IV. DISCUSSION
We found that diabetic patients who took metformin had a lower 
recurrence rate of colorectal adenoma than those who did not take metformin. In 
addition, metformin use was associated with a lower cumulative rate of colorectal 
adenoma recurrence after adjustment for age, sex, body mass index, diabetes 
mellitus duration, aspirin use, insulin use, thiazolidinedione use, HbA1c, number 
of baseline adenomas, and time to first follow-up colonoscopy in diabetic patients 
with previous colorectal adenoma.
Recent studies have shown that diabetes is associated with increased
risks of colorectal adenoma and adenocarcinoma.20,21 Therefore, the potential 
preventive effect of metformin against colorectal adenoma contributes to a lower 
incidence of colorectal adenoma and adenocarcinoma in patients with diabetes. 
Moreover, on the basis of the accumulated evidence on dosage and safety, 
metformin has the potential for use as a chemopreventive agent for the general 
population.
In this study, the metformin group showed higher body mass index, 
higher HbA1c, and lower insulin use. We believe that the reason for these 
differences is that metformin is usually used as first-line therapy for diabetes and 
is preferred in obese patients. Because these could be important factors that can 
affect the development of adenoma and cancer, we included these factors in the 
adjustment for confounding factors. Our univariate and multivariate logistic 
regression analyses showed no association between those factors and the 
recurrence of adenoma.
In the aspect of adenoma recurrence, the metformin group showed lower 
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recurrence of total adenoma. However, there was no significant difference in the 
recurrence of advanced adenoma. Our previous study about the effect of 
metformin on the recurrence of colorectal adenoma in diabetic patients with 
previous colorectal cancer showed similar results.18 These results suggest that 
metformin might suppress the early steps in the adenoma-carcinoma sequence,
before the adenoma becomes an advanced adenoma. Therefore, more data from a 
larger cohort or population with a long-term surveillance duration are needed to 
confirm the long term effect of metformin on advanced adenoma and CRC.
In the subgroup analysis according to sex, we found that there was a 
significant difference in the recurrence of total adenoma between metformin users
and non-users among male patients but not among female patients. Although the 
number of female patients was too small for an exact evaluation, hormonal (e.g., 
estrogen) differences could be related factors in the sex-dependent difference of 
adenoma recurrence according to metformin use.22
In addition, as combined anti-diabetic drugs, we analyzed the use of 
thiazolidinedione, which has a chemopreventive effect, and insulin, which is 
related to tumor growth in colorectal cancer. Takahashi et al. reported 
PPARgamma agonist, an anti-diabetic drug, as a promising candidate for 
colorectal cancer chemoprevention in their pilot study.23 Moreover, there are some 
reports about the effect of thiazolidinedione on decreased risk and mortality of 
other types of cancer. Meanwhile, a high level of insulin is related to tumor growth 
and carcinogenesis.24 Therefore, we included the use of thiazolidinedione and 
insulin into the multivariate analysis. Although our data did not show a significant 
association of these two drugs with adenoma recurrence, we could not perform 
22
meaningful analysis owing to the small number of patients taking these two drugs.
As for the aspirin, a well-known chemopreventive drug for colorectal 
adenoma and cancer did not affect the recurrence of adenoma in our analysis of
factors affecting the recurrence rate of colorectal adenoma. We surmise that this 
different result might be because of the small number of patients taking aspirin 
and the specific study cohort, in which all patients have diabetes and a significant 
proportion of whom take metformin.
This study has several limitations. First, this study is retrospective in 
nature, which means unexpected bias cannot be completely ruled out. We did not 
have data on noncompliance to metformin treatment, which could have resulted in 
exposure misclassification and biased results. Additional study limitations 
included the small sample size, which reduced the power of detecting significant 
differences in adenoma recurrence, although our findings showed significant 
results. Finally, because the data analyzed in this study population were collected 
from a tertiary medical care unit, the results may not be generalizable to the 
general population. Furthermore, because this study included patients with 
diabetes, it is difficult to generalize the chemopreventive effect of metformin 
patients without diabetes. 
Recently, a multi center double-blinded placebo-controlled trial was 
reported by Takuma et al. Their study demonstrated that metformin reduced the 
prevalence and number of adenomas in non-diabetic patients.25,26 However, the 
sample size of the study was small and the follow-up duration was only 1 year. 
Therefore, to generalize the results, long-term clinical trials with larger samples 
involving diverse populations are needed. In addition, like our study, more 
23
retrospective data from a diverse population with a long-term follow-up duration 
could be helpful for designing and performing future large-scale prospective 
studies.
24
V. CONCLUSION
Metformin use in diabetic patients has a potential chemoprevention effect 
against colorectal adenoma. To generalize the use of metformin for the prevention 
of colorectal adenoma, a large-scale randomized controlled trial with a long term 
follow-up duration is needed.
25
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ABSTRACT (IN KOREAN)
메포민이 대장선종을 절제한 당뇨환자에서
대장선종의 재발에 미치는 영향 분석
<지도교수 김태일>
연세대학교 대학원 의학과
한 민 석
메포민의 복용이 대장암 환자의 예후와 대장암 발생에
긍정적인 영향이 있다는 것은 이미 알려져 있다. 하지만 메포민이
대장암의 전구인 대장 선종에 미치는 영향에 대해서는 아직 알려진
자료가 적다. 따라서 본 연구는 대장 선종을 절제한 당뇨환자에서
메포민 복용이 대장 선종의 재발에 미치는 영향을 분석해 보고자
하였다. 2005년부터 2011년까지 대장 선종 절제를 받고 다시 추적
대장 내시경을 시행 받은 423명의 환자를 대상으로 연구를
진행하였으며, 최종적으로 257명의 환자가 분석되었다. 
메포민을 복용 중인 106명의 환자에서 38명(35.8%)이
대장선종의 재발을 보였으나, 메포민을 복용하지 않는 151명의
환자에서는 85명(56.3%)이 대장선종의 재발을 보였다 (P = 0.001). 대장
선종의 재발에 영향을 미치는 인자에 대한 Cox 다변량 분석에서
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메포민의 복용은 대장 선종의 재발을 감소시키는 유의한 인자로
확인되었다 (Hazard ratio 0.572, 95% Confidence interval 0.385-0.852, P = 
0.006). 또한 메포민을 복용한 군이 메포민을 복용하지 않는 군에
비해 대장 선종의 누적 재발 가능성도 유의하게 낮았다 (P = 0.001). 
이상의 결과로 당뇨환자에서 메포민의 복용은 대장 선종의
재발을 억제하는 효과가 있음을 시사한다.
------------------------------------------------------------------------------------------------
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